Home » Investors

Investors

Extra General Meeting, 14 December 2022

BICO GROUP AB (PUBL)

BICO by Numbers

  • Net sales Jan-Sep 2022
    0 MSEK
  • Organic growth Jan-Sep 2022
    0 %
  • Employees
    0 +
  • Instruments in the field
    0 +
  • Publications
    0 +
  • Countries
    0 +

Press Releases

01/05/23RegulatoryBICO appoints COO
01/02/23RegulatoryBICO Group Appoints New CFO
Erik Gatenholm
President & CEO
Mikael Engblom
Interim Group CFO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areasBioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO.

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.